Clinical Trials Logo

Mantle-Cell Lymphomas clinical trials

View clinical trials related to Mantle-Cell Lymphomas.

Filter by:
  • None
  • Page 1

NCT ID: NCT02650999 Completed - Clinical trials for Follicular Lymphomas

Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas

Start date: January 2016
Phase: Phase 1/Phase 2
Study type: Interventional

Single center, phase I/II trial of pembrolizumab after CTL019 for CD19+ lymphomas. Patients will have CD19+ diffuse large B-cell, follicular, or mantle cell lymphomas relapsed/refractory after CTL019. 12 total patients will be enrolled. Safety of pembrolizumab (primary endpoint) will be determined using a Bayesian monitoring rule for treatment-related adverse events causing drug discontinuation. Secondary efficacy endpoints include overall response rate and progression-free survival.

NCT ID: NCT00877214 Active, not recruiting - Clinical trials for Non-Hodgkin's Lymphoma

Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas

MAINTAIN
Start date: April 1, 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if an extended maintenance therapy with Rituximab in follicular and a maintenance therapy in other indolent and mantle cell lymphomas has advantages compared to a shorter or no maintenance therapy.